Ye Junxiao, Liu Ergang, Gong Junbo, Wang Jianxin, Huang Yongzhuo, He Huining, Yang Victor C
Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
Collaborative Innovation Center of Chemical Science and Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China.
Theranostics. 2017 Jun 25;7(9):2495-2508. doi: 10.7150/thno.19863. eCollection 2017.
Because of the unparalleled efficiency and universal utility in treating a variety of disease types, siRNA agents have evolved as the future drug-of-choice. Yet, the inability of the polyanionic siRNA macromolecules to cross the cell membrane remains as the bottleneck of possible clinical applications. With the cell penetrating peptides (CPP) being discovered lately, the most effective tactic to achieve the highest intracellular siRNA delivery deems to be by covalently conjugating the drug to a CPP; for instance, the arginine-rich Tat or low molecular weight protamine (LMWP) peptides. However, construction of such a chemical conjugate has been referred by scientists in this field as the "Holy Grail" challenge due to self-assembly of the cationic CPP and anionic siRNA into insoluble aggregates that are deprived of the biological functions of both compounds. Based on the dynamic motion of PEG, we present herein a concise coupling strategy that is capable of permitting a high-yield synthesis of the cell-permeable, cytosol-dissociable LMWP-siRNA covalent conjugates. Cell culture assessment demonstrates that this chemical conjugate yields by far the most effective intracellular siRNA delivery and its corresponded gene-silencing activities. This work may offer a breakthrough advance towards realizing the clinical potential of all siRNA therapeutics and, presumably, most anionic macromolecular drugs such as anti-sense oligonucleotides, gene compounds, DNA vectors and proteins where conjugation with the CPP encounters with problems of aggregation and precipitation. To this end, the impact of this coupling technique is significant, far-reaching and wide-spread.
由于在治疗多种疾病类型方面具有无与伦比的效率和广泛的实用性,小干扰RNA(siRNA)药物已逐渐成为未来的首选药物。然而,带负电的siRNA大分子无法穿过细胞膜仍然是其临床应用的瓶颈。随着细胞穿透肽(CPP)的发现,实现最高细胞内siRNA递送的最有效策略被认为是将药物与CPP共价偶联;例如,富含精氨酸的Tat肽或低分子量鱼精蛋白(LMWP)肽。然而,由于阳离子CPP和阴离子siRNA自组装形成不溶性聚集体,从而丧失了两种化合物的生物学功能,该领域的科学家将构建这种化学偶联物称为“圣杯”挑战。基于聚乙二醇(PEG)的动态运动,我们在此提出一种简洁的偶联策略,该策略能够高产率地合成可穿透细胞、可在细胞质中解离的LMWP-siRNA共价偶联物。细胞培养评估表明,这种化学偶联物产生了迄今为止最有效的细胞内siRNA递送及其相应的基因沉默活性。这项工作可能为实现所有siRNA疗法的临床潜力带来突破性进展,并且据推测,对于大多数阴离子大分子药物,如反义寡核苷酸、基因化合物、DNA载体和蛋白质,当与CPP偶联遇到聚集和沉淀问题时,也具有重要意义。为此,这种偶联技术的影响是重大的、深远的和广泛的。